Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert B Jenkins

Showing results (71-80 of 269) with videos related to

Pageof 27
Sort By:
Journal of Neuropathology and Experimental Neurology|July 23, 2024
Comparing loss of p16 and MTAP expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytomaM Adelita Vizcaino, Caterina Giannini, Rachael A Vaubel, et al.
Cancer|February 25, 2003
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical featuresMartin J van den Bent, Leendert H J Looijenga, K Langenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trialEdith A Perez, Vera J Suman, Nancy E Davidson, et al.
Neuro-Oncology|January 12, 2013
Clinical significance and novel mechanism of action of kallikrein 6 in glioblastomaKristen L Drucker, Alex R Paulsen, Caterina Giannini, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 12, 2002
Risk of cancer among relatives of patients with gliomaBrian P O'Neill, Hannes Blondal, Ping Yang, et al.
Journal of the National Cancer Institute|June 6, 2002
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831Patrick C Roche, Vera J Suman, Robert B Jenkins, et al.
Archives of Pathology & Laboratory Medicine|April 28, 2009
Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelinesGail H Vance, Todd S Barry, Kenneth J Bloom, et al.
Journal of Neuro-Oncology|July 5, 2014
The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytomaSani H Kizilbash, Caterina Giannini, Jesse S Voss, et al.
International Journal of Cancer|May 21, 2016
Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinomaHarry H Yoon, Mark A Lewis, Nathan R Foster, et al.
Neuro-Oncology|June 27, 2002
Prognostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high-grade astrocytomasHiroko Kuriyama, Kathleen R Lamborn, Judith R O'Fallon, et al.
Pageof 27

Showing results (71-80 of 269) with videos related to

Sort By:
Pageof 27
Journal of Neuropathology and Experimental Neurology|July 23, 2024
Comparing loss of p16 and MTAP expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytomaM Adelita Vizcaino, Caterina Giannini, Rachael A Vaubel, et al.
Cancer|February 25, 2003
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical featuresMartin J van den Bent, Leendert H J Looijenga, K Langenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trialEdith A Perez, Vera J Suman, Nancy E Davidson, et al.
Neuro-Oncology|January 12, 2013
Clinical significance and novel mechanism of action of kallikrein 6 in glioblastomaKristen L Drucker, Alex R Paulsen, Caterina Giannini, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 12, 2002
Risk of cancer among relatives of patients with gliomaBrian P O'Neill, Hannes Blondal, Ping Yang, et al.
Journal of the National Cancer Institute|June 6, 2002
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831Patrick C Roche, Vera J Suman, Robert B Jenkins, et al.
Archives of Pathology & Laboratory Medicine|April 28, 2009
Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelinesGail H Vance, Todd S Barry, Kenneth J Bloom, et al.
Journal of Neuro-Oncology|July 5, 2014
The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytomaSani H Kizilbash, Caterina Giannini, Jesse S Voss, et al.
International Journal of Cancer|May 21, 2016
Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinomaHarry H Yoon, Mark A Lewis, Nathan R Foster, et al.
Neuro-Oncology|June 27, 2002
Prognostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high-grade astrocytomasHiroko Kuriyama, Kathleen R Lamborn, Judith R O'Fallon, et al.
Pageof 27